NYSE - Delayed Quote USD

Penumbra, Inc. (PEN)

206.15 +0.45 (+0.22%)
As of April 24 at 4:00 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Adam Elsesser Co-Founder, Chairman, President & CEO 601.62k 3.66M 1962
Dr. Arani Bose M.D. Co-Founder & Director 37.5k -- 1962
Ms. Maggie S. Yuen Chief Financial Officer 660.98k -- 1973
Mr. Lambert Shiu Chief Accounting Officer 539.15k 269.12k 1981
Ms. Johanna Roberts Executive VP, General Counsel & Secretary 655.75k 4.61M 1972
Mr. Ben Sorci Executive Vice President of Operations -- -- --
Mr. Pankaj Tiwari Executive VP & Chief Information Officer -- -- --
Ms. Jee Hamlyn-Harris Investor Relations Officer -- -- --
Mr. Ben Tompkins Executive Vice President of Development -- -- --
Ms. Gita Barry President of Immersive Healthcare -- -- --

Penumbra, Inc.

One Penumbra Place
Alameda, CA 94502
United States
510 748 3200 https://www.penumbrainc.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
4,200

Description

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Corporate Governance

Penumbra, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 7; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024
Penumbra, Inc. Earnings Call

Related Tickers